Holds one active US DMF for letermovir, filing since 2021. Its 2025 FDA inspection closed as VAI, and its GMP is recognised in 30 markets.
Holds one active US DMF for letermovir, filing since 2026. Its 2024 FDA inspection closed as VAI, and its GMP is recognised in 4 markets.
Holds one active US DMF for letermovir, filing since 2021. Its 2025 FDA inspection closed as VAI, and its GMP is recognised in 25 markets.
Holds one active US DMF for letermovir, filing since 2025. Its 2024 FDA inspection closed as NAI, and its GMP is recognised in 2 markets.
Holds one active US DMF for letermovir, filing since 2025. Its 2019 FDA inspection closed as VAI, and its GMP is recognised in 2 markets.
This page filters the worldwide Letermovir manufacturer list to companies based in India. The order is set by active filings weighted by regulator, inspection outcomes and their recency, breadth of GMP recognition, and evidence of real exports, less any open risk flags. Read the full method.
Tell us which markets you need to file in. These suppliers come back tiered for those markets, with the price corridor and an RFI sheet.
Start for free